Ablative Therapy for Oligometastatic Disease: Where Are We Now and Where Are We Going?

The oligometastatic state is a proposed stage between localized cancer and widely metastatic disease, comprising an intermediate subset of metastatic cancer patients. Daniel Gomez, M.D., will discuss the future directions, including randomized trials, that explore the role of ablative therapy in oligometastatic disease.  

Target Audience

Oncologists, Radiation Oncologists, Hematology Oncologists, Radiation Therapists, General Surgeons, General Practitioners, Obstetricians and Gynecologists, Nurses, Patient Navigators and all other interested healthcare professionals.
 

Learning Objectives

  • Define the various stages of oligometastatic disease and the biologic implications of each.
  • Analyze the current oligometastatic literature and the rationale for ablative therapy.
  • Summarize future directions, including randomized trials, that explore the role of ablative therapy in oligometastatic disease.
Additional information
Bibliography: 
  • Palma, D. A., Olson, R., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., ... & Senan, S. (2019). Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. The Lancet, 393(10185), 2051-2058.
  • Gomez, D. R., Blumenschein Jr, G. R., Lee, J. J., Hernandez, M., Ye, R., Camidge, D. R., ... & Heymach, J. V. (2016). Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. The lancet oncology, 17(12), 1672-1682.
  • Wang, X. S., Bai, Y. F., Verma, V., Yu, R. L., Tian, W., Ao, R., ... & Zeng, M. (2022). Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer. JNCI: Journal of the National Cancer Institute.
Course Summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 General certificate of attendance
  • 1.00 Nurse Practitioners
  • 1.00 Florida Board of Nursing
Course opens: 
02/01/2023
Course expires: 
12/31/2024
Part of: 
Miami Cancer Institute Multispecialty e-Learning Series

Daniel Gomez, M.D., MBA
Director of Thoracic Radiation Oncology and
Vice Chair of Clinical Operations
Department of Radiation Oncology
Memorial Sloan Kettering Cancer Center
New York, New York
                
Daniel Gomez, M.D., faculty for this educational activity, is a researcher for Varian, AstraZeneca, Merck and BMS. He is a consultant for GRAIL, Olympus, Medtronic, Johnson and Johnson and Varian; and a member of the speakers’ bureau for MedLearning Group. Dr. Gomez has indicated that the presentation or discussion will not include off-label or unapproved product usage. 

Guilherme Rabinowits, M.D., conference director of this educational activity, is an advisor with Sanofi-Genzyme, Regeneron, Castle and Boston Gene. 

All of the relevant financial relationships listed for these individuals have been mitigated.

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies*.

*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Disclosure Policy and Disclaimer

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
              
Baptist Health South Florida designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 General certificate of attendance
  • 1.00 Nurse Practitioners
  • 1.00 Florida Board of Nursing
Please login or register for a Baptist Health CME account to take this course.

Required Hardware/Software

PC/Mac Users
PC/Mac Users

This site is supported on the most recent stable releases of the following browsers:

Click Here to Download Google Chrome
Google Chrome		Microsoft Edge
Microsoft Edge		Safari
Safari		Moxilla Firefox
Mozilla Firefox
Internet Explorer

Attention: Internet Explorer Users
This site offers limited support for Internet Explorer 11 (IE11). When using IE11, you will be prompted to download course videos instead of viewing them in the browser. After the course video downloads, the recordings will play.

Mobile Users
Mobile Users

This site is supported on the following mobile devices:

  • Apple iOS mobile devices running iOS 10 or later
  • Android mobile devices running Android 4.4 or later, with the latest release of Google Chrome or Mozilla Firefox
Technical Support
Technical Support

If you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.